Saturday

08:30 - 10:30 HALL A
B1:	GESTATIONAL DIABETES Capsule: Despite increasing knowledge many questions remained unanswered.
	Chairpersons:	D.R. Coustan, USA M. Hod, Israel G.H. Breborowicz, Poland
	08:30	IS IT A CLINICAL ENTITY? SHOULD WE SCREEN? D.R. Coustan, USA
	08:50	CAN FETAL WEIGHT BE ESTIMATED ACCURATELY? WHAT IS THE SIGNIFICANCE? Z. Hagay, Israel
	09:10	CAN MACROSOMIA BE PREVENTED? M. Hod, Israel
	09:30	TIMING AND MODE OF DELIVERY; VAGINAL VS CS DELIVERY S. Kjos, USA
	09:50	INDUCTION OF LABOR IN GESTATIONAL DIABETES J. Atad, Israel
	10:10	CAN SHOULDER DYSTOCIA BE PREVENTED? I. Blickstein, Israel
	10:30	Coffee Break
11:00 - 13:00 HALL A
B8:	MANAGEMENT OF TWIN PREGNANCY Capsule: Twins increase pregnancy complications.
	Chairpersons:	F. Chervenak, USA L.G. Keith, USA D. Farine, Canada
	11:00	CONTROVERSIES IN ZYGOSITY ASSESSMENT L.G. Keith, USA
	11:25	THE BEST TIME TO ESTABLISH ZYGOSITY I. Meizner, Israel
	11:50	DIFFERENT MODE OF MANAGEMENT FOR TTS N.M. Fisk, UK
	12:15	CESAREAN SECTION FOR ALL TWINS? I. Blickstein, Israel
	12:40	ETHICAL CONTROVERSIES IN THE MANAGEMENT OF MULTIPLE PREGNANCIES F. Chervenak, USA
	13:00	Lunch Break
14:30 - 16:30 HALL A
E1:	THE HORMONE CONTINUUM Capsule: A disease Prevention Strategy During the 4th and 5th Decades of Life Sponsored by: Johnson & Johnson
	Chairpersons:	J.S. Lippman, USA
	14:30	WELCOME AND INTRODUCTION J.S. Lippman, USA
	14:35	OVERVIEW - THE HORMONE CONTINUUM: A DISEASE PREVENTION STRATEGY J.S. Lippman, USA
	14:55	BREAST CANCER REVIEW (Ocs/HRT) AND NONCONTRACEPTIVE HEALTH BENEFITS ASSOCIATED WITH CONTINUED HORMONE USE L.P. Shulman, USA
	15:20	DISFUNCTIONAL UTERINE BLEEDING J. Lippman, USA
	15:45	RATIONALE FOR THE HORMONE CONTINUUM DURING THE 4^TH AND 5^TH DECADES OF LIFE AND THE TRANSITION TO HRT A.M. Kaunitz, USA
	16:10	QUESTIONS AND ANSWERS Panel
	16:25	SUMMARY AND CONCLUSIONS A.M. Kaunitz, USA
	16:30	Coffee Break
17:00 - 19:00 HALL A
E2:	ORAL CONTRACEPTION Capsule: OC are most commonly used. Is it suitable for adolescents and women over 40?
	Chairpersons:	J. Horejsi, Czech Republic G. Creatsas, Greece V. Bruni, Italy
	17:00	GYNECOLOGICAL EXAMINATION IN CHILDREN - (PRO) J. Horejsi, Prague, Czech Republic
	17:20	IS THERE ANY JUSTIFICATION TO REDUCE ESTROGEN DOSES? M. Short, Ireland
	17:40	CONTRACEPTION FOR ADOLESCENT GIRLS (PRO) G. Creatsas, Greece
	18:00	CONTRACEPTION FOR ADOLESCENT GIRLS (CON) V. Bruni, Italy
	18:20	STD's AND ORAL CONTRACEPTION V. Unzeitig, Czech Republic
	18:40	CONTRACEPTION IN THE 4th AND 5th DECADE OF LIFE M. Short, Ireland
08:30 - 10:30 HALL B + C
A6:	MICROMANIPULATION Capsule: Micromanipulation is being used in increasing frequency and seems safe.
	Chairpersons:	P.N. Barri, Spain J.J. Cohen, France P. Devroey, Belgium
	08:30	SHOULD ICSI BE APPLIED TO ALL IVF CYCLES? W. Schoolcraft, USA
	08:55	GENETIC TESTING AND COUNSELING BEFORE ICSI IS CONSIDERED P. Devroey, Belgium
	09:20	INHERITANCE OF INFERTILITY - DANGERS FOR GENERATIONS DOWNSTREAM A.O. Trounson, Australia
	09:45	THE ROLE OF CYTOPLASMTIC TRANSFER R.G. Gosden, UK
	10:10	PREIMPLANTATION GENETIC DIAGNOSIS BY POLAR BODY BIOPSY Y. Verlinsky, USA
	10:30	Coffee Break
11:00 - 12:00 HALL B + C
A9:	MEDICAL MANAGEMENT OF ENDOMETRIOSIS, UTERINE FIBROIDS AND DYSFUNCTIONAL UTERINE BLEEDING Capsule: Does hysterectomy still have a place in modern management? Sponsored by:AstraZeneca
	Chairperson:	D. Olive, USA
	00:01	SURGICAL MANAGEMENT J. Donnez, Belgium
	00:02	MEDICAL MANAGEMENT E. Thomas, UK
12:00 - 13:00 HALL B + C
A3:	ENDOMETRIOSIS Capsule: A mystery tour for the clinician and patient? Sponsored by:AstraZeneca
	Chairperson:	D. Olive, USA
	00:01	FERTILITY EXPERT W. Ledger, UK
	00:02	ENDOMETRIOSIS EXPERT W. Schlaff, USA
	13:00	L u n c h B r e a k
14:30 - 16:30 HALL B + C
B2:	ATOSIBAN - A SPECIFIC EVOLUTION FOR THE MANAGEMENT OF PRETERM LABOUR Capsule: The debate continues, is there a safe way to arest preterm labour? Sponsored by: Ferring Pharmaceuticals
	Chairperson:	P.J. Steer, UK
		INTRODUCTION P.J. Steer, UK
		US PLACEBO-CONTROLLED TRIALS OF ATOSIBAN IN THE TREATMENT OF PRETERM LABOUR T.M. Goodwin, USA
		WORLDWIDE COMPARATIVE TRIALS OF ATOSIBAN IN THE TREATMENT OF PRETERM LABOUR R.F. Lamont, UK
		CLINICAL SIGNIFICANCE OF ATOSIBAN IN THE TREATMENT OF PRETERM LABOUR J-M. Moutquin, Canada
		INTERACTIVE DEBATE D. Cabrol, UK, K. Marstal, Sweden
		INTERACTIVE QUESTION AND ANSWER FORMAT P. J.Steer, UK
		CONCLUSION P.J. Steer, UK
	16:30	Coffee Break
17:00 - 18:30 HALL B + C
B5:	MULTIPLE PREGNANCY REDUCTION Capsule: ART and ovulation induction increased the rate of multiple pregnancies.
	Chairpersons:	R. Frydman, France T. Mardesic, Czech Republic Z. Ben-Rafael, Israel
	17:00	TIMING - FIRST OR SECOND TRIMESTER? S. Lipitz, Israel
	17:22	THE DILEMMA OF TRIPLETS - TO REDUCE OR NOT TO REDUCE? - HOW MANY IN ONE SESSION - THE TECHNIQUE? I.E. Timor, USA
	17:45	SHOULD WE REDUCE TO ONE? T. Mardesic, Czech Republic
	18:08	MULTIPLE REDUCTION - GENETIC DIAGNOSIS BEFORE OR AFTER? I.E. Timor, USA